Industry to benefit from EU moves to cut red tape
This article was originally published in Scrip
Six measures being taken to simplify the EU pharmaceutical legislation, including new rules on side-effect reporting and changes to marketing authorisations, could significantly reduce the administrative burden on companies and lead to savings of around €155 million, says the European Commission.
You may also be interested in...
The coronavirus could have serious adverse effects on regulatory procedures at both European Medicines Agency and EU member state level. A new business continuity plan describes how procedures will be prioritized if problems arise.
Coronavirus Update: Setback With Hydroxychloroquine, Slowdown In UK ADR Reports, But Novel Drugs Begin Trials
In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national, European and global level.
Participants in a recent webinar looked at how the coronavirus is changing the way we look at clinical trials and whether new EU COVID-19 guidance might hold lessons for future approaches to study design.